证券代码：688151 证券简称：华强科技 公告编号：2025-003 湖北华强科技股份有限公司 关于控股股东拟发生变更的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 2 月 9 日，湖北华强科技股份有限公司（以下简称"本公司"）接到 控股股东中国兵器装备集团有限公司（以下简称"兵器装备集团"）通知，兵器装 备集团正在与其他国资央企集团筹划重组事项。本次重组或将导致本公司控股股 东发生变更，但不会导致实际控制人发生变更。有关安排尚需履行程序，还需获 得有关主管部门批准。本次重组不会对本公司正常生产经营活动构成重大影响。 本次重组事项，尚处于筹划阶段，有关事项具有不确定性，敬请投资者注意 风险。 特此公告。 湖北华强科技股份有限公司董事会 2025 年 2 月 10 日 1 为保证及时、公平地披露信息，维护广大投资者利益，现予以公告。后续， 本公司将严格按照信息披露要求，持续关注有关进展并根据相关法律法规的要求 及时履行信息披露义务。 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 18 million and 26.9 million yuan, an increase of 10.07 million to 18.97 million yuan compared to the previous year, representing a year-on-year increase of 127% to 239%[3] - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is expected to be between -75.3 million and -52.9 million yuan, an increase of 0.73 million to 2.31 million yuan compared to the previous year, representing a year-on-year increase of 1% to 30%[3] - The total profit for 2023 was 4.1426 million yuan, with a net profit attributable to shareholders of the parent company of 7.9251 million yuan, and a net profit after deducting non-recurring gains and losses of -76.0274 million yuan[5] Factors Influencing Profit - The increase in profit is primarily due to the company's efforts to solidify its civilian product base, aggressively expand market orders, and secure military product orders, leading to increased revenue from military products and improved capacity utilization[7] - The company has optimized its product structure, resulting in increased sales of high-margin products[7] - Non-operating income increased due to adjustments in deposit structure, leading to higher investment income[8] Audit and Investment Risks - The performance forecast data has not been audited by a registered accounting firm[4] - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change upon the release of the audited annual report[10]

å ˆå Ώ໌Œæ–¹ç¾å—ç›–ç« 之日起生效，履行期é™ 自å ˆå Œç¾è®¢ä¹‹æ— ¥èµ·è‡³2025å¹´12月15日。 ' 该å ˆå Œä¸ºå…¬å¸æ—¥å¸¸ç»è ¥æ€§å ˆå Œï¼Œæ — 需æ 交董事会ã€股东大会审议。 è´¢è"社1月10日电，å Žå¼ºç§'技公告，公å¸ä¸ŽæŸ å •ä½ ç- ¾ç½²äº†ç‰¹ç§ 防护领域业务相关的销售å ˆå Œï¼Œå ˆå Œé‡'é¢ 为1.45亿元。 å ˆå Œçš"履行æ å ‡äº†å…¬å¸åœ¨ç‰¹ç§ 防护领域的一体化科ç "生产和æ‰ ¿æŽ¥é‡ 大项目的能力，预计未æ ¥ä¼šå¯¹å…¬å¸ç»è ¥ä¸šç»©äº§ç"Ÿç§¯æžå½±å" 〠...

Group 1: Market Demand and Product Development - The market demand for biological safety laboratory positive pressure protective clothing is significant, catering to domestic bio-safety level 4 laboratories and disease control centers, filling a national gap and breaking through technical barriers from developed countries [2] - The company has been focusing on the development of medical packaging products for over 30 years, aiming for "safer, more convenient, and more environmentally friendly" solutions, including advanced drug packaging components and systems [4] - The company is expanding its market presence in Southeast Asia while optimizing its product structure to meet the growing global pharmaceutical market demands [4] Group 2: Strategic Adjustments and Technological Advancements - The procurement model for special protective equipment has changed post-military reform, with individual military branches now ordering based on their needs, allowing for customized services [4] - The company is advancing its protective materials research towards systematization, integration, and intelligence, enhancing overall equipment performance and environmental adaptability [6] - The company maintains independent business operations and strong collaboration with military units, ensuring autonomous research and development capabilities [6]

Investment Rating - The report assigns a "Buy" rating to the company based on its industry position and future development prospects [20][25]. Core Insights - The company specializes in pharmaceutical packaging, particularly in the production of medicinal butyl rubber stoppers, multi-layer co-extruded films, medical masks, and protective clothing, with high product quality and profit margins [1]. - The company has established itself as a leader in the domestic medicinal butyl rubber stopper industry, having pioneered the localization of production and the intelligent manufacturing process [1][10]. - The company has formed long-term partnerships with major pharmaceutical groups and has received numerous accolades for its innovative products [1][10]. - The company is actively expanding into new markets, including cosmetic stoppers and veterinary medicine stoppers, to meet evolving market demands [9][10]. Summary by Sections Company Overview - The company is a key player in the pharmaceutical packaging sector, recognized for its high-quality products and significant market share in medicinal butyl rubber stoppers [1][10]. - It has been involved in drafting important industry standards and guidelines, enhancing its reputation and influence within the sector [1]. Product Development - The company has developed various types of medicinal butyl rubber stoppers, including conventional stoppers, film-coated stoppers, and rubber components for pre-filled syringes, which are crucial for drug safety and efficacy [4][10]. - Recent innovations include the development of high-barrier film materials and new types of stoppers designed for sensitive and high-activity pharmaceuticals [11][10]. Financial Projections - The company is projected to achieve revenues of 577 million yuan, 629 million yuan, and 710 million yuan for the years 2024, 2025, and 2026, respectively, with corresponding net profits of 35.27 million yuan, 40.16 million yuan, and 46.22 million yuan [21][25]. - The expected growth rates for revenue and net profit indicate a positive outlook for the company's financial performance in the coming years [21][25]. Market Position - The company benefits from a robust marketing network and stable customer base, having established long-term relationships with major pharmaceutical enterprises [10][11]. - The demand for special protective equipment and pharmaceutical packaging is expected to grow, driven by increasing awareness of safety and quality in the healthcare sector [20][25].

证券代码：688151 证券简称：华强科技 公告编号：2024-044 湖北华强科技股份有限公司 本次会议是否有被否决议案：无 2024 年第三次临时股东大会决议公告 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 12 月 12 日 （二） 股东大会召开的地点：中国（湖北）自贸区宜昌片区生物产业园东临路 499 号湖北华强科技股份有限公司会议室 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 192 | | --- | --- | | 普通股股东人数 | 192 | | 2、出席会议的股东所持有的表决权数量 | 267,365,307 | | 普通股股东所持有表决权数量 | 267,365,307 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 77.6096 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量 ...

力.州大厦 A 座 14-16 层 Beijing Dacheng Law Offices, LLP(Yichang) 14-16 F, Tower A, Jiuzhou Building No.72, Yiling Avenue, Xiling District 443000, Yichang, Hubei, China 北京大成(宜昌)律师事务所 关于湖北华强科技股份有限公司 2024 年第三次临时股东大会的 法 律 意 见 书 大成 is Dentons'Preferred Law Firm in China. 北京大成(宜昌)律师事务所 www.dacheng.com 湖北省宜昌市西陵区夷陵大道 72 号九州大厦 A 座 14-16 层(443000) 14-16 F, Tower A, Jiuzhou Building No.72, Yiling Avenue, Xiling District ,443000, Yichang, Hubei, China Tel:+86 027-6919599 大成 is Dentons' Preferred Law Firm in China. 北京大成(宜昌)律 ...

证券代码：688151 证券简称：华强科技 湖北华强科技股份有限公司投资者关系活动记录表 编号：2024-015 | --- | --- | --- | |----------------|-------------------------|---------------------------------------------------------------------------------------------------------| | | □ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 ☑路演活动 | | | □ 现场调研 □其他 | | | 参与单位名称 | | 稳泰基金、兴聚基金、平安基金、银河证券、江海证券、深 圳吉石资本、融中投资、卫光生物、深圳瑞沃德、九水投 | | | 资、天源资产评估 | | | 时间 | 2024 年 12 月 8 | 日（星期日）下午 14:00-16:00 | | 地点 | | 深圳市光明区天安云谷国际会议中心会议厅 | | 上市公司 | | | | 接待人员姓名 | ...

Group 1: Investor Relations Activity - The company participated in the "Q3 2024 Earnings Presentation" at the Shanghai Stock Exchange Roadshow Center on December 2, 2024 [1][2] - The event was attended by key personnel including the General Manager and Secretary of the Board [2] Group 2: Cost Control Measures - The company has implemented measures to enhance quality and efficiency, focusing on lean management and cost control [4] - Accounts receivable have decreased year-on-year, and inventory has also been reduced [4] - The company is utilizing commercial bills and supply chain finance to save on funding costs [4] Group 3: Q3 Financial Performance - For Q3 2024, the company reported revenue of 34,200 million yuan and a total profit of 2,709 million yuan [4] - Strategies to improve operational quality include expanding market reach and optimizing product market structure [4] - The company is focusing on technological innovation and increasing investment in research and development [4]

2024 年第三次临时股东大会会议资料 证券代码：688151 证券简称：华强科技 湖北华强科技股份有限公司 2024 年第三次临时股东大会 会议资料 二〇二四年十二月 2024 年第三次临时股东大会会议资料 目 录 | 湖北华强科技股份有限公司 | 2024 | 年第三次临时股东大会会议须知 | 1 | | --- | --- | --- | --- | | 湖北华强科技股份有限公司 | 2024 | 年第三次临时股东大会会议议程 | 4 | | 议案一 ：关于聘请 2024 | | 年度审计机构的议案 | 6 | 2024 年第三次临时股东大会会议资料 湖北华强科技股份有限公司 2024 年第三次临时股东大会会议须知 为维护全体股东的合法权益，确保股东大会的正常秩序和议事效率， 保证股东大会的顺利进行，根据《中华人民共和国公司法》（以下简称《公 司法》）、《中华人民共和国证券法》以及《湖北华强科技股份有限公司 章程》（以下简称《公司章程》）、《湖北华强科技股份有限公司股东大 会议事规则》等相关规定，湖北华强科技股份有限公司（以下简称"公司"） 特制定 2024 年第三次临时股东大会会议须知： 一、为确认出 ...